Browse PLAC1

Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain -
Function

May play a role in placental development.

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0060712 spongiotrophoblast layer development
GO:0061458 reproductive system development
GO:0090214 spongiotrophoblast layer developmental growth
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLAC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PLAC1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29632317Breast carcinomaInhibit immunityEO771 "knockdown" (KD) resulted in 50% reduction in proliferation in vitro and impaired tumor growth in syngeneic mice; however, tumor growth in SCID mice was equivalent to tumor cells expressing a non-silencing control RNA, suggesting that Plac1 regulated adaptive immunity.
29704427Breast CarcinomaInhibit immunityCancer/testis Antigen-Plac1 Promotes Invasion and Metastasis of Breast Cancer through Furin/NICD/PTEN Signaling Pathway. Overexpression of Plac1 promoted invasion and metastasis of breast cancer cells in vitro and in vivo. Co-immunoprecipitation and immunofluorescence cell staining assays revealed that interaction of Plac1 and Furin degraded Notch1 and generated Notch1 intracellular domain (NICD) that could inhibit PTEN activity.
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLAC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLAC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5750.0383
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9840.0724
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2810.515
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5460.0942
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.5850.0915
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2420.904
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7260.348
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5670.693
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.9570.528
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2310.72
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2310.796
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4670.14
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLAC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLAC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLAC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLAC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLAC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLAC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLAC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLAC1
Nameplacenta-specific 1
Aliases CT92; OOSP2L; cancer/testis antigen 92; Placenta-specific protein 1
Chromosomal LocationXq26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLAC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.